This mechanism aligns with broader evidence that dysregulated JAK-STAT signaling is a convergent axis of treatment resistance across multiple cancers, including TNBC and hepatocellular carcinoma (HCC). Here, SOAT1 is linked to hepatocellular carcinoma.